ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $3.63 billion. The enterprise value is $4.71 billion.

Market Cap	3.63B
Enterprise Value	4.71B

Important Dates

The next estimated earnings date is Monday, November 11, 2024, before market open.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

ImmunityBio has 696.53 million shares outstanding. The number of shares has increased by 51.44% in one year.

Shares Outstanding	696.53M
Shares Change (YoY)	+51.44%
Shares Change (QoQ)	+2.10%
Owned by Insiders (%)	42.40%
Owned by Institutions (%)	9.97%
Float	165.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	33.29
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3,601.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.91

Current Ratio	3.91
Quick Ratio	3.54
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.50

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-61.04%
Return on Capital (ROIC)	-94.39%
Revenue Per Employee	$2,083
Profits Per Employee	-$951,667
Employee Count	628
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-40,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +69.16% in the last 52 weeks. The beta is -0.35, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y)	-0.35
52-Week Price Change	+69.16%
50-Day Moving Average	3.84
200-Day Moving Average	5.16
Relative Strength Index (RSI)	63.27
Average Volume (20 Days)	8,455,841

Short Selling Information

The latest short interest is 51.58 million, so 7.41% of the outstanding shares have been sold short.

Short Interest	51.58M
Short Previous Month	52.68M
Short % of Shares Out	7.41%
Short % of Float	31.17%
Short Ratio (days to cover)	20.99

Income Statement

In the last 12 months, ImmunityBio had revenue of $1.31 million and -$597.65 million in losses. Loss per share was -$0.95.

Revenue	1.31M
Gross Profit	1.31M
Operating Income	-359.17M
Pretax Income	-601.00M
Net Income	-597.65M
EBITDA	-341.06M
EBIT	-359.17M
Loss Per Share	-$0.95

Full Income Statement

Balance Sheet

The company has $217.98 million in cash and $998.96 million in debt, giving a net cash position of -$780.98 million or -$1.12 per share.

Cash & Cash Equivalents	217.98M
Total Debt	998.96M
Net Cash	-780.98M
Net Cash Per Share	-$1.12
Equity (Book Value)	-697.38M
Book Value Per Share	-1.01
Working Capital	180.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$410.00 million and capital expenditures -$15.62 million, giving a free cash flow of -$425.62 million.

Operating Cash Flow	-410.00M
Capital Expenditures	-15.62M
Free Cash Flow	-425.62M
FCF Per Share	-$0.61

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-27,459.25%
Pretax Margin	-45,704.13%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-136,703.97%

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-51.44%
Shareholder Yield	-51.44%
Earnings Yield	-15.21%
FCF Yield	-10.83%

Analyst Forecast

The average price target for ImmunityBio is $17.38, which is 233.59% higher than the current price. The consensus rating is "Buy".

Price Target	$17.38
Price Target Difference	233.59%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmunityBio has an Altman Z-Score of -10.96 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.96
Piotroski F-Score	3